Product Name: LIN28B antibody
Applications: IHC-P, WB
Predicted Target Size: 27 kDa (note)
Positive Controls: Huh7
Form Supplied: Liquid
Concentration: 0.51 mg/ml (Please refer to the vial label for the specific concentration)
Purification: Purified by antigen-affinity chromatography.
Full Name: lin-28 homolog B (C. elegans)
Background: Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5-GGAG-3 motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5-GGAG-3 motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.
Synonyms: lin-28 homolog B (C. elegans) Antibody , CSDD2 Antibody
Cellular Localization: Cytoplasm , Nucleus
CAS NO: 943962-47-8
Product: Arg-Gly-Asp-Ser
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: Recombinant protein encompassing a sequence within the center region of human LIN28B. The exact sequence is proprietary.
Antigen Species: Human
Species Reactivity: Human
Conjugation: Unconjugated
Storage Buffer: 1XPBS, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative.
Storage Instruction: Keep as concentrated solution. Aliquot and store at -20ÂșC or below. Avoid multiple freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/25196310?dopt=Abstract
